Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Biomarkers for personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30. Review.

PMID:
25468140
2.

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.

Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR.

Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31.

PMID:
23117072
3.

Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.

Ther Drug Monit. 2011 Apr;33(2):244-50. doi: 10.1097/FTD.0b013e31820beb02.

PMID:
21311410
4.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
5.

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.

Wang Y, Zhou L, Dutreix C, Leroy E, Yin Q, Sethuraman V, Riviere GJ, Yin OQ, Schran H, Shen ZX.

Br J Clin Pharmacol. 2008 Jun;65(6):885-92. doi: 10.1111/j.1365-2125.2008.03150.x. Epub 2008 Apr 1.

Supplemental Content

Loading ...
Support Center